Patent search cpc:"G01N2500/04" Page 8

71.

发明申请
METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS INFECTIONS 审中-公开

公开(公告)号：US20170266197A1

公开(公告)日：2017-09-21

申请号：US15310070

申请日：2015-05-11

Applicant: Indiana University Research and Technology Corporation , Assembly Biosciences, Inc.

Inventor： Adam Zlotnick , William W. Turner , Lee Daniel Arnold

IPC: A61K31/5377 , A61K31/506 , G01N33/50 , A61K31/445 , G01N33/576 , A61K45/06 , A61K31/18

CPC classification number: A61K31/5377 , A61K31/18 , A61K31/445 , A61K31/506 , A61K31/713 , A61K45/06 , G01N33/5023 , G01N33/5032 , G01N33/5762 , G01N2500/04

Abstract: Described herein are methods for identifying compounds useful for the treatment of infection by hepatitis B virus (HBV) and for identifying compounds useful for the same.

72.

发明授权
Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment 有权

公开(公告)号：US09737592B1

公开(公告)日：2017-08-22

申请号：US14624460

申请日：2015-02-17

Applicant: David Gordon Bermudes , David Quintero

Inventor： David Gordon Bermudes , David Quintero

IPC: A61K38/55 , C07K14/81 , C12Q1/37

CPC classification number: A61K38/55 , C07K14/81 , C12Q1/37 , G01N2333/81 , G01N2500/04 , G01N2500/10 , Y02A50/473

Abstract: The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and/or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and/or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and/or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.

73.

发明申请
IDENTIFICATION OF IMMUNOLOGICALLY PROTECTIVE NEO-EPITOPES FOR THE TREATMENT OF CANCERS 审中-公开

公开(公告)号：US20170224799A1

公开(公告)日：2017-08-10

申请号：US15501919

申请日：2015-09-03

Applicant: THE UNIVERSITY OF CONNECTICUT , UNIVERSITY OF NOTRE DAME DUE LAC

Inventor： PRAMOD K. SRIVASTAVA , BRIAN M. BAKER

IPC: A61K39/00 , C12Q1/68 , G01N33/68 , G01N33/574

CPC classification number: A61K39/0011 , A61K39/39533 , A61K2039/5158 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/574 , G01N33/6878 , G01N2333/70539 , G01N2500/04 , A61K2300/00

Abstract: Described herein are methods of identifying immunologically protective neo-epitopes from the cancer tissue DNA of cancer patients using biophysical principles as well as bioinformatics techniques. The identification of immunologically protective neo-epitopes provides pharmaceutical compositions with a limited number of tumor-specific peptides suitable for personalized genomics-driven immunotherapy of human cancer. Specifically disclosed herein is a method of using the conformational stability of an epitope in an MHC protein-binding groove to predict immunogenicity of peptides in a putative neo-peptide set from a tumor from a cancer patient. Pharmaceutical compositions and methods of administration are also included.

74.

发明授权
Modulators of CFTR 有权

公开(公告)号：US09725440B2

公开(公告)日：2017-08-08

申请号：US14633278

申请日：2015-02-27

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Sara Hadida-Ruah , Mark Miller , Brian Bear , Jinglan Zhou , Jason McCartney , Peter Grootenhuis

IPC: C07D405/14 , C07D213/75 , C07D401/04 , A61K31/444 , G01N33/50

CPC classification number: C07D405/14 , A61K31/444 , C07D213/75 , C07D401/04 , G01N33/502 , G01N2333/705 , G01N2500/04 , G01N2500/10

Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

75.

发明申请
MARKER SEQUENCES FOR DIAGNOSING AND STRATIFYING SYSTEMIC SCLEROSIS PATIENTS 审中-公开

公开(公告)号：US20170199202A1

公开(公告)日：2017-07-13

申请号：US15324470

申请日：2015-07-04

Applicant: PROTAGEN AG

Inventor： Petra BUDDE , Peter SCHULZ-KNAPPE , Angelika LÜKING , Martin GAMER

IPC: G01N33/68 , C07K16/40 , C07K16/18 , G01N33/564 , C07K14/47

CPC classification number: G01N33/6893 , C07K14/47 , C07K16/18 , C07K16/40 , C07K2317/33 , C07K2317/34 , G01N33/564 , G01N2500/04 , G01N2800/24 , G01N2800/52

Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.

76.

发明申请
METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION, DIAGNOSTIC AGENT, THERAPEUTIC AGENT, AND SCREENING METHOD FOR SAID AGENTS 审中-公开

公开(公告)号：US20170182012A1

公开(公告)日：2017-06-29

申请号：US15107502

申请日：2014-12-25

Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY

Inventor： Hitoshi OKAZAWA

IPC: A61K31/437 , G01N33/68 , C12Q1/48

CPC classification number: A61K31/437 , A61K31/44 , A61K31/4439 , A61K31/506 , C12Q1/485 , G01N33/6896 , G01N2500/04 , G01N2500/20 , G01N2800/2821

Abstract: It has been revealed that, from a pre-onset stage of Alzheimer's disease, enhancement of phosphorylations of MARCKS and the like causes abnormal spine formation or the like, consequently developing the disease. Moreover, it has also been revealed that the phosphorylations of MARCKS and the like are caused by PKC and the like, and further that b-raf is involved in the phosphorylation of a tau protein important for the progression of Alzheimer's disease. Thus, these proteins have been found to be target molecules useful in the diagnosis and treatment of Alzheimer's disease. In addition, it has also been revealed that, in a pre-onset stage of frontotemporal lobar degeneration also, b-RAF phosphorylation enhancement causes a decrease in the number of spines and the like, consequently developing the disease. Thus, b-RAF has been found to be a target molecule useful in the diagnosis and treatment of frontotemporal lobar degeneration.

77.

发明申请
METHOD FOR INHIBITING INTRACELLULAR ACTIVATED RAS USING INTACT IMMUNOGLOBULIN-TYPE ANTIBODY HAVING CYTOSOL-PENETRATING ABILITY AND USE THEREOF 审中-公开

公开(公告)号：US20170158777A1

公开(公告)日：2017-06-08

申请号：US15327539

申请日：2015-07-22

Applicant: ORUM THERAPEUTICS INC.

Inventor： Yong-Sung Kim , Dong-Ki Choi , Seung-Min Shin , Sung-Hoon Kim

IPC: C07K16/40 , C07K7/06 , G01N33/68

CPC classification number: C07K16/40 , A61K2039/505 , C07K7/06 , C07K16/32 , C07K16/44 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/00 , C12Y306/05002 , G01N33/566 , G01N33/5748 , G01N33/6854 , G01N2333/914 , G01N2500/04

Abstract: The present invention relates to a method for inhibiting intracellular activated RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol. The present invention also relates to a heavy-chain variable region (VH) which induces an intact immunoglobulin-type antibody to actively penetrate the cytosol of living cells through endocytosis and endosomal escape and to bind to activated RAS in the cytosol, and to an antibody comprising the same. The present invention also relates to a method of inhibiting the growth of cancer or tumor cells and a method of treating cancer or tumor, by use of the antibody. The present invention also relates to a method for screening a heavy-chain variable region that binds specifically to RAS in the cytosol. The present invention also relates to a biologically active molecule fused to the antibody and selected from the group consisting of peptides, proteins, small-molecule drugs, nanoparticles and liposomes. The present invention also relates to a composition for prevention, treatment or diagnosis of cancer, comprising: the antibody; or a biological active molecule fused to the antibody and selected from the group consisting of peptides, proteins, small-molecule drugs, nanoparticles and liposomes. The present invention also relates to a polynucleotide that encodes the light-chain variable region and the antibody.According to the present invention, the method for inhibiting intracellular activated RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol is achieved by allowing the antibody to penetrate living cells and to specifically recognize activated (GTP-bound) RAS in the cytosol. Thus, the antibody can target activated (GTP-bound) RAS in the cytosol of living cells and inhibit the activity of the RAS.Furthermore, the antibody light-chain variable region according to the present invention and an antibody comprising the same is able to penetrate living cells and localize in the cytosol, without having to use a special external protein delivery system. Particularly, the antibody light-chain variable region according to the present invention can easily interact with various human heavy-chain variable regions (VHs) and has the ability to penetrate the cytosol and remain in the cytosol, and an intact IgG-type monoclonal antibody comprising the light-chain variable region can penetrate cells and localize in the cytosol, and shows no cytotoxicity non-specific for target cells.The antibody heavy-chain variable region according to the present invention and an antibody comprising the same can selectively inhibit mutations of the major drug resistance-related factor RAS of conventional various tumor therapeutic agents, and can exhibit synergistic anticancer activity with conventional therapeutic agents. In addition, the cytosol-penetrating, intact immunoglobulin-type antibody according to the present invention can penetrate cells and remain in the cytosol, without affecting the high specificity and affinity of a human antibody heavy-chain variable region (VH) for antigens, and thus can localize in the cytosol which is currently classified as a target in disease treatment based on small-molecule drugs, and at the same time, can exhibit high effects on the treatment and diagnosis of tumor and disease-related factors that show structurally complex interactions through a wide and flat surface between protein and protein.

78.

发明申请
COMPOSITIONS AND METHODS RELATED TO TAUOPATHY 审中-公开

公开(公告)号：US20170145067A1

公开(公告)日：2017-05-25

申请号：US15425514

申请日：2017-02-06

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Karen Hsiao Ashe , Xiaohui Zhao , Michael Anthony Walters , Derek John Hook , Morgan Clotaire Paul Le Naour

IPC: C07K14/47

CPC classification number: C07K14/4711 , A61K38/00 , C07K16/18 , C07K2317/34 , C12Q1/37 , G01N2500/04 , G01N2800/2821

Abstract: Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2.